1-31-12:  FDA  has just approved 2 new diabetes drugs:

1)  Amylin’s BYDUREON™

Amylin Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved BYDUREON™, the first once-weekly treatment for type 2 diabetes. BYDUREON™ is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes in multiple clinical settings. BYDUREON™ will be available in pharmacies nationwide in February, 2012.

More info at:  http://phx.corporate-ir.net/phoenix.zhtml?c=101911&p=irol-newsArticle&ID=1653756

2)  Boehringer Ingelheim and Eli Lilly’s Jentadueto™ 

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved Jentadueto™(linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin. Jentadueto™ provides a new, single-tablet treatment option, taken twice-daily, for patients who need to control their blood sugar.

More info at:  http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2012/january_30_2012.html

Mary Ann Hodorowicz, RD, CDE, MBA, Certified Endocrinology Coder
PresentDiabetes Author of MNT and DSMT Reimbursement Audio Lectures

Eat Well, Laugh Often, Love Much